CVE:TLT - Theralase Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$0.30 +0.01 (+1.69 %) (As of 01/18/2019 04:00 PM ET)Previous CloseC$0.30Today's RangeC$0.30 - C$0.3152-Week RangeC$0.19 - C$0.46Volume81,850 shsAverage Volume78,792 shsMarket CapitalizationN/AP/E Ratio-10.00Dividend YieldN/ABetaN/A ProfileDiscussionChartEarningsHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Photo Dynamic Therapy and Therapeutic Laser Technology. The company also designs, manufactures, and distributes super-pulsed cool laser technology for the treatment of pain for knees, nerves, muscles, and joints, as well as for in off-label use. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories. The company is also developing TLD-1433, an anti-cancer drug, which is in Phase 1B clinical trial for non-muscle invasive bladder cancer. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada. Receive TLT News and Ratings via Email Sign-up to receive the latest news and ratings for TLT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange CVE Industry Medical Appliances & Equipment Sub-IndustryN/A SectorMedical Current SymbolCVE:TLT Previous Symbol CUSIPN/A Webtheralase.com Phone+1-416-6995273Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.56Price-To-Earnings Trailing P/E Ratio-10.00 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$2.26 million Price / Sales17.85 Cash FlowC$0.00 per share Price / Cash Flow78.75 Book ValueC$0.00 per share Price / Book75.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees20 Outstanding Shares134,743,000Market CapC$0.00 OptionableOptionable Theralase Technologies (CVE:TLT) Frequently Asked Questions What is Theralase Technologies' stock symbol? Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT." When is Theralase Technologies' next earnings date? Theralase Technologies is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for Theralase Technologies. Has Theralase Technologies been receiving favorable news coverage? News articles about TLT stock have been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Theralase Technologies earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. Who are some of Theralase Technologies' key competitors? Some companies that are related to Theralase Technologies include Bioquell (BQE), Consort Medical (CSRT), Corindus Vascular Robotics (CVRS), Deltex Medical Group (DEMG), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), InspireMD (NSPR), LiDCO Group (LID), Lucid (LCDX), Medaphor Group (MED), Smith & Nephew (SN), Verisante Technology (VRS) and Zecotek Photonics (ZMS). Who are Theralase Technologies' key executives? Theralase Technologies' management team includes the folowing people: Dr. Arkady Mandel, Interim CEO & Chief Scientific OfficerMs. Kristina Hachey, Chief Financial OfficerMr. Roger John Dumoulin-White, Director of Bus. Devel.Mr. David M. Groves B.A, Pres of World Trade DivisionDr. James R. Andrews (ASMI), M.D., Chairman of Medical & Scientific Advisory Board and Medical Director (Age 76) How do I buy shares of Theralase Technologies? Shares of TLT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Theralase Technologies' stock price today? One share of TLT stock can currently be purchased for approximately C$0.30. What is Theralase Technologies' official website? The official website for Theralase Technologies is http://theralase.com/. How can I contact Theralase Technologies? Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The company can be reached via phone at +1-416-6995273. MarketBeat Community Rating for Theralase Technologies (CVE TLT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 37 (Vote Outperform)Underperform Votes: 34 (Vote Underperform)Total Votes: 71MarketBeat's community ratings are surveys of what our community members think about Theralase Technologies and other stocks. Vote "Outperform" if you believe TLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: Do Tariffs Work?